The economic burden of rare diseases based on direct, indirect, and mortality-related costs is 10 times greater than the burden for mass market diseases, such as diabetes and cardiovascular disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback